Abstract

Inflammatory bowel disease (IBD) affects millions worldwide and causes chronic GI inflammation, complications and reduced quality of life [1]. Current therapies often fail to prevent inflammation-driven intestinal fibrosis, and many patients still require surgery for strictures.

Researchers at McMaster University have discovered a modular therapeutic platform using the tryptophan-derived metabolite to reduce gastrointestinal inflammation and inhibit inflammation-associated intestinal fibrosis. Delivered systemically or enterically, the approach restores a suppressed endogenous anti-inflammatory pathway, lowers pro-inflammatory and pro-fibrotic mediators, and reduces collagen deposition in preclinical colitis models. The formulation concept is adaptable (oral, enteric, or parenteral) and can be combined with excipients that enhance bioavailability while preserving the core pharmacology.

Applications

• Therapeutic for IBD patients at risk of inflammation-driven intestinal fibrosis (Crohn’s disease, ulcerative colitis).
• Adjunct therapy to reduce post-inflammatory strictures and delay or avoid surgical interventions.

Advantages

• Reduces both inflammation and fibrosis where many drugs only suppress inflammation.
• Demonstrated efficacy in multiple preclinical colitis models, including T-cell transfer and DSS.
• Flexible administration routes and excipient formulations to improve bioavailability and targeting.